Loading...
Docoh

Cybin (CYBN)

82 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
6-K
CYBN Cybin Inc.
28 Jun 22
Cybin Announces Additional Adelia Milestone Achievement
3:54pm
6-K
CYBN Cybin Inc.
27 Jun 22
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
1:15pm
40-F
2022 FY
CYBN Cybin Inc.
22 Jun 22
Annual report (Canada)
7:32am
6-K
CYBN Cybin Inc.
22 Jun 22
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
7:31am
6-K
CYBN Cybin Inc.
16 Jun 22
Current report (foreign)
1:17pm
6-K
CYBN Cybin Inc.
9 Jun 22
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
5:07pm
6-K
CYBN Cybin Inc.
7 Jun 22
Cybin Acquires DMT Clinical Study from Entheon Biomedical
11:32am
6-K
CYBN Cybin Inc.
6 Jun 22
Cybin Announces Additional Adelia Milestone Achievements
10:52am
6-K
CYBN Cybin Inc.
3 Jun 22
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
11:35am
6-K
CYBN Cybin Inc.
3 Jun 22
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
10:41am
6-K
CYBN Cybin Inc.
2 Jun 22
Current report (foreign)
12:23pm
6-K
CYBN Cybin Inc.
31 May 22
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
5:00pm
6-K
CYBN Cybin Inc.
17 May 22
Current report (foreign)
11:16am
6-K
CYBN Cybin Inc.
11 May 22
Current report (foreign)
4:24pm
6-K
CYBN Cybin Inc.
9 May 22
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
4:20pm
6-K
CYBN Cybin Inc.
4 May 22
Current report (foreign)
8:00pm
D
CYBN Cybin Inc.
28 Apr 22
$2.89M in options / Stock option grants, sold $2.89M, 9 investors
11:43am
D
CYBN Cybin Inc.
28 Apr 22
$342.51K in options / Stock option grants, sold $342.51K, 5 investors
11:40am
6-K
CYBN Cybin Inc.
22 Apr 22
Current report (foreign)
2:14pm
6-K
CYBN Cybin Inc.
21 Apr 22
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
2:13pm